Axovant Gene Therapies Ltd.
(NASDAQ : AXGT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 1.60%78.211.0%$1948.71m
AMGNAmgen, Inc. -1.66%205.411.3%$885.20m
REGNRegeneron Pharmaceuticals, Inc. -1.09%493.322.6%$821.01m
BIIBBiogen, Inc. -1.30%300.511.5%$730.72m
MRNAModerna, Inc. 4.94%34.840.0%$587.89m
VRTXVertex Pharmaceuticals, Inc. -1.59%238.311.9%$585.26m
ILMNIllumina, Inc. -3.48%263.503.5%$455.53m
ALXNAlexion Pharmaceuticals, Inc. -0.64%89.772.0%$278.42m
AAgilent Technologies, Inc. -2.63%70.391.6%$217.41m
INCYIncyte Corp. 1.97%78.592.5%$187.57m
EXASEXACT Sciences Corp. -3.21%55.7521.0%$173.77m
BMRNBioMarin Pharmaceutical, Inc. -2.15%84.214.3%$161.37m
SGENSeattle Genetics, Inc. -1.82%116.516.1%$157.34m
NVAXNovavax, Inc. 12.63%15.61114.7%$131.54m
SRPTSarepta Therapeutics, Inc. -2.46%93.6214.0%$100.23m

Company Profile

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.